We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Vitamin D3 Fights Cancer by Activating a Tumor Suppressor Gene

By LabMedica International staff writers
Posted on 20 Jul 2009
Cancer researchers have determined the molecular basis for the antitumor action of the active form of vitamin D3, 1-alpha,25-dihydroxyvitamin D3 (calcitriol).

While the mode of action of this form of vitamin D3 is not completely understood, investigators have interpreted the results of transcriptomatic studies (evaluation of cellular mRNA expression) carried out on a human colon cancer cell line as showing that vitamin D3 directly activated the gene for cystatin D (CST5). More...


Cystatin D is a member of the cystatin superfamily of endogenous inhibitors of endosomal/lysosomal cysteine proteases. Cystatins have been reported to play a role in diverse biological processes, including cell proliferation, differentiation, survival, migration, and interleukin and nitric oxide production. Cystatin D has a more restricted pattern of tissue expression and a narrower inhibitory profile than other cystatins: it inhibits cathepsin S, H, and L but not cathepsin B.

In the current study, investigators at the Universidad Autónoma de Madrid (Spain) and the Universidad de Oviedo (Spain) investigated the regulation and biological activity of the CST5 gene in colon cancer. In their report, which was published in the July 6, 2009, issue of the Journal of Clinical Investigation, they presented evidence that vitamin D3 was linked to the direct transcriptional regulation of the human CST5 gene in colon cancer cells. Their results also showed that cystatin D profoundly affected the cell phenotype, inhibiting proliferation and migration and increasing cell adhesiveness.

Experiments where the expression of cystatin D was "knocked down" showed that human colon cancer cells lacking this activity were unresponsive to the antiproliferative effects of the active form of vitamin D3.

The authors concluded the study by saying, "CST5 is a candidate tumor suppressor gene, and it mediates a large proportion of the anticancer effects of the active form of vitamin D3. These data provide rationale for clinical trials examining the preventive and therapeutic potential of the active form of vitamin D3 in colon cancer."

Related Links:
Universidad Autónoma de Madrid
Universidad de Oviedo



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.